# **Top Management Presentation**

# Financial Results for Fiscal 2010 (April 1, 2010 to March 31, 2011)

Friday, May 13, 2011 Joji Nakayama, President and CEO



# **Key Topics in FY2011**




Maintain/Expand Core Business	Expansion in Emerging Markets	Sharp Focus/ Reinforcement in R&D	
Japan •Expand Innovative	•Further Growth in	•Oncology	
Pharmaceuticals Business	India		
•Strengthen Established Pharmaceuticals, OTC, and Vaccine Businesses	<ul> <li>Accelerate</li> <li>business growth</li> <li>in China</li> </ul>	<ul> <li>Steady progress on Edoxaban development</li> </ul>	
US/Europe • Maintain and expand			
Olmesartan franchise			
Maximize Effient <sup>®</sup> /Efient <sup>®</sup>			



**Effient<sup>®</sup>: Factors of increased growth (US)** 

Company (Alliance)	<ul> <li>Successful execution of customer centric sales model</li> <li>Focused sales efforts in high volume PCI centers and key OAP prescribers Effient<sup>®</sup> uptake for formulary and protocol inclusion is improved significantly</li> <li>Effective promotional messages in high risk ACS-PCI patients</li> </ul>
Customer (Market)	• Strong recommendations in ACC/AHA STEMI* and UA**/NSTEMI*** guidelines *STEMI = ST elevation myocardial infarction ** UA = unstable angina *** NSTEMI = non-ST elevation myocardial infarction
Competitor	• Increased awareness of limitations of the current OAP* therapy * OAP = Oral Anti Platelet






\* New to Brand is an early indicator for future growth of the brand, which consists of thienopyridine naiive patients and switching patients from other brand



5

Source: IMS NPA

## Share of Effient<sup>®</sup>, Hospital, PCI Market



Source: IMS NDTI December 2009, IMS NSP Retail and Non-Retail Sales




Source: SDI Data

# Sales Growth of Effient<sup>®</sup>/Efient<sup>®</sup>

## Effient<sup>®</sup>/Efient<sup>®</sup> Sales Expansion

- Launch: Europe (March '09), US (August '09)
- October 2010:Re-execute Marketing approach for enhancing sales growth
- Boost by additional indication, TRILOGY ACS (Planned conclusion: Apr-2012)





## **Optimally harness marketing capability**

Optimally allocate dominant Japanese network of 2,400 MRs to maximize sales clout

#### Maximize Olmesartan revenues

Boost combined domestic sales of Olmetec and Rezaltas by 26%, to ¥110 billion in fiscal 2011

#### **Seamless launch of new products**

- Fiscal 2010 : Four products (Rezaltas, Loxonin Gel, Inavir, and Cravit IV)
- Fiscal 2011 : Memary (to launch on June 8) Lixiana (approved on April 22) Esomeprazole Denosumab



## **Product Availability**

### Active pharmaceutical ingredients (API)

#### Pravastatin

- Manufactured at Onahama (Japan)
- Production to restart in September, shipping from November 2011
- Sufficient inventory held for domestic and overseas markets

#### Olmesartan

- Manufactured at Odawara and Onahama (Japan)
- Capacity increased at Odawara
- Secure sufficient inventory by partly operating during holidays in May and June
- ✓ Further enhancement of capacity under consideration

#### **Drug Formulations**

#### Main products including Olmesartan

- Made mainly at Hiratsuka (Japan)
- Secure **sufficient inventory** by partly operating on holidays
- Backup production at Takatsuki (Japan) and Phaffenhofen (Germany)

#### Memary


- API from Merz Pharma (Germany), formulation and packaging at Hiratsuka (Japan)
- Currently securing stable supplies, planning to launch on June 8

#### **Other products**

- **Boosting capacity at Hiratsuka**, by partly operating on holidays
- Outsource some production to other plants and companies as needed

## Secure stable supply of Main Products







## **Expansion in Emerging Markets: India**

### **Strategic Intent**

Achieve true potential as a leader in the country, to capitalize on strong growth in the Indian Pharmaceuticals Market (IPM), and to grow faster than the IPM

Estimated market growth: US\$12.6 Bn (2009) to US\$35~70 Bn (2020) CAGR 10~17%



# Project VIRIAN by Ranbaxy

- Field force expansion from 3,200 (2009) to 4,200 (2011)
- More number of product launches
- Further strengthen areas where Ranbaxy has a lead
  - Urban market, Acute therapy segment
- Focus on areas where Ranbaxy have room for strong growth
  - Rural market, Hospital segment, Chronic therapy segment

Rank			MAT Mar 2011			Jan – Mar 2011		
MAT		Company	Sales	MS	YoY growth	Sales	MS	YoY growth
MAT YTD		INR Bn	%	%	INR Bn	%	%	
1	1	CIPLA	250.7	5.20	13.3	63.9	5.39	12.1
2	2	RANBAXY	227.0	4.71	12.1	56.6	4.78	17.3
3	3	GLAXOSMITHKLINE	201.5	4.18	11.9	47.7	4.03	7.9
4	5	PIRAMAL HEALTHCARE	189.7	3.93	6.4	46.4	3.92	0.8
5	6	ZYDUS CADILA	180.0	3.73	15.7	44.6	3.77	12.9
		Total IPM	482.4	100.00	15.3	118.5	100.00	13.6



### **Strategic Intent**

Increase presence in a fast-growing, highly attractive Chinese market (Fifth largest drug market in the world)



# Invest aggressively to lift sales from 800 million RMB in fiscal 2010, to 3 billion RMB in fiscal 2015

- Streamline two operations in Beijing and Shanghai and strengthen marketing capabilities, increasing number of MRs from 450 to 700 in 2015
- Expand regionally by adding more MRs and forming alliances, increasing adoption in hospital to further increase sales of Cravit and Olmetec
- Strengthen portfolio, largely by securing external resources through inlicensing, partnerships, and acquisitions



## **Acquisition of Plexxikon**

## Profile

- Established in Berkeley, California, in 2001 (unlisted)
- CEO: K. Peter Hirth, Ph.D.
- Approximately 45 employees

#### Secure late-stage compounds

Reinforce oncology capabilities and accelerate market entry

#### **Build technological foundation**

- Scaffold-Based Drug Discovery<sup>™</sup> Platform
- Platform for personalized medicine
- Research presence in San Francisco bay area

#### Pipeline


- PLX4032 (for Metastatic Melanoma): partnering with Roche, NDA filed in US/EU
- PLX3397 (for Hodgkin lymphoma: In Phase II trials)
- PLX5622 (for rheumatoid arthritis): In Phase I trials
- followed by multiple preclinical compounds








## **Global Research Functions**



## **Steady Progress in Oncology Pipeline**





## Memo



# **Financial Overview**



**Overview of Income Statement** 


#### **Ranbaxy Group**

Note : Figures of Ranbaxy are pre-adjusted before consolidation


		FY2009	FY2010	FY2011		2009	2010	2011(Jan-Dec)	
		Results	Results	Forecast	YoY	(Jan-Dec) Results	(Jan-Dec) Results	Forecast	YoY
Net Sales		952.1	967.4	970.0	2.6	146.7	173.1	162.0	-11.1
Cos	t of Sales	278.0	281.7	290.0	8.3	75.4	79.8		
SG	&A Expenses	578.6	563.5	590.0	26.5	64.9	65.6		
	R&D Expenses	196.8	194.3	200.0	5.7	10.3	12.0		
	Other Expenses	381.8	369.2	390.0	20.8	54.6	53.5		
-	erating come	95.5	122.1	90.0	- 32.1	6.3	27.7		
	dinary come	103.1	131.8	90.0	- 41.8	13.0	40.0		
Ne	t Income	41.9	70.1	45.0	- 25.1	4.2	23.3		

JPY Bn












## Overview of FY2010 Results - compared with FY2009 results -






	Forecast as of Jan	FY2010 Results (Apr-Mar)	Difference	
Net Sales	965.0	967.4	2.4	
Cost of Sales	280.0	281.7	1.7	
SG&A Expenses	565.0	563.5	-1.5	
R&D Expenses	194.0	194.3	0.3	
Other Expenses	371.0	369.2	-1.8	Decrease in promotion expenses due to disast
Operating Income	120.0	122.1	2.1	Non-operating gain/los •Ranbaxy related forex gain
Ordinary Income	125.0	131.8	6.8	Extraordinary income/le •Loss on disaster -5.6
Net Income	70.0	70.1	0.1	
			JPY Bn	

JPY Bn




22





23






24

## **Sales of Major Products**

					JPY Bn
		FY2009 Results	FY2010 Results		011 cast
	Olmesartan	238.3	241.5	270.0	11.8%
GIO	Levofloxacin	87.2	69.1	53.0	-23.3%
Global	Pravastatin	55.0	44.9	38.0	-15.3%
	Prasugrel (alliance revenue)	0.5	5.2	-	
	Loxonin	47.0	54.2	58.0	7.1%
L	Artist	23.3	23.7	23.0	-3.0%
Japan	Omnipaque	27.3	25.0	23.0	-8.0%
5	Calblock	13.7	14.0	15.0	7.5%
	Urief	9.0	10.1	11.0	9.4%
U.S	Welchol	27.5	28.5	32.0	12.2%
Ś	Venofer	32.2	30.7	25.0	-18.5%
Currency Rate (average) EUR/JPY (average)		92.86	85.72	83	.00
		131.16	113.13	115	5.00

**Regional sales of Olmesartan** 





## **Major R&D Pipeline**

Therapeutic Area	Phase 1	Phase 2	Phase 3	Application
Cardiovascular- Metabolics	<ul> <li>CS-3150 (Antihypertensive)</li> <li>DS-7309 (Anti-diabetes)</li> </ul>	<ul> <li>DU-176b (US/EU)</li> <li>(Edoxaban / post surgical VTE / oral factor Xa inhibitor)</li> <li>CS-747 (JP)</li> <li>(Prasugrel / ischemic stroke / anti-platelet agent)</li> <li>CS-1036 (JP/Acia)</li> <li>(Glucose absorption inhibitor)</li> </ul>	<ul> <li>DU-176b (US/EU/JP/Asia) (Edoxaban / AF / oral factor Xa inhibitor)</li> <li>DU-176b (US/EU/JP/Asia) (Edoxaban / VTE / oral factor Xa inhibitor)</li> <li>☆CS-747 (US/EU/Asia) (Prasugrel / ACS-MM / anti-platelet agent)</li> <li>CS-747 (JP) (Prasugrel / ACS-PCI / anti-platelet agent)</li> </ul>	DU-176b (JP) (Edoxaban / post surgical VTE / oral factor Xa inhibitor)
Oncology	<ul> <li>CS-7017(JP/Asia) (Efatutazone / PPAR γ agonist)</li> <li>U3-1565 (US) (Anti-HB-EGF antibody)</li> <li>U3-1287(JP) (Anti-HER3 antibody)</li> <li>DS-2248(US) (Hsp90 inhibitor)</li> </ul>	<ul> <li>U3-1287 (US/EU)         <ul> <li>(Anti-HER3 antibody)</li> <li>CS-1008 (US/EU/JP/Asia)</li> <li>(Tigatuzumab / anti-DR5 antibody)</li> <li>CS-7017 (US/EU)                  <li>(Efatutazone / PPAR γ agonist)</li> <li>DE-766 (JP)</li></li></ul></li></ul>	ARQ 197 (US/EU) (Tivantinib / NSCLC / c-Met inhibitor)	PLX4032 (US/EU) (Vemurafenib / Melanoma / BRAF inhibitor)
Infectious diseases	<ul> <li>CS-8958(US/EU)</li> <li>(Laninamivir / anti-influenza / co-development with Biota)</li> <li>CS-4771 (Anti-Sepsis)</li> <li>DS-8587</li> <li>(Broad spectrum antibacterial agent)</li> </ul>		■ ☆CS-8958 (JP) (Laninamivir / anti-influenza, prophylactic / Neuraminidase inhibitor)	
Bone/Joint diseases	PLX5622 (Rheumatoid arthritis)	■ AMG 162 (JP) (Denosumab / rheumatoid arthritis / anti-RANKL antibody)	■ AMG 162 (JP) (Denosumab / osteoporosis, breast cancer adjuvant / anti-RANKL antibody)	■ AMG 162 (JP) (Denosumab / bone metastases of cancer / anti-RANKL antibody)
Immunological allergic diseases	CS-0777 (Immunomodulator)	SUN13834 (US) (Chymase inhibitor)		
Others	<ul> <li>DS-5565 (Chronic pain)</li> <li>SUN13837 (Spinal cord injury)</li> </ul>	SUN11031 (US/EU) (Human ghrelin / COPD cachexia)	<ul> <li>■ SUN11031 (JP)</li> <li>(Human ghrelin / anorexia nervosa)</li> <li>■ ☆DD-723-B (JP)</li> <li>(Perflubutane / Contrast agents in ultrasound for prostate cancer and breast tumor/ ultrasound contrast agent)</li> </ul>	■ KMD-3213 (China) (Silodosin / treatment of dysuria associated with benign prostatic hyperplasia/ Selective alpha 1A blocker)


• Change from the announcement in January 2011

 $\bigstar$  Additional indications, new formulations etc.

PLX4032(Melanoma/BRAF inhibitor/US/EU/Application), PLX3397 (Fms/Kit/Flt3-ITD inhibitor/US/P2), PLX5622 (Rheumatoid arthritis/P1), □ New (underline) DS-7309(Anti-diabetes/P1), DS-2248 (Hsp90 inhibitor/P1), SUN13837(Spinal cord injury/P1) Daiichi-Sankyo DU-176b(Post surgical VTE/oral factor Xa inhibitor/JP/Approved) □ Change of Stage

Discontinued etc. CS-1036(Glucose absorption inhibitor/JP/Asia/P2)

## Movement since January 2011 update





#### **Contact address regarding this material**

## Daiichi Sankyo Co., Ltd. Corporate Communications Department

#### TEL: +81-3-6225-1126

Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk and uncertainty.

For this reason, the actual performance data, etc. may differ from the prospective value.